This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA) issued two guidance documents, one draft and one final, on food allergen labeling requirements. 1, 2023; The applicability of food allergen labeling requirements to specific products (e.g., 1, 2023; The applicability of food allergen labeling requirements to specific products (e.g.,
Draft guidance published by the US Food and Drug Administration (FDA) in December 2023, discussed quality considerations for topical ophthalmic drug products, including key considerations for extractables and leachables (E&L) testing. This document is revised from a version published in October 2023.
Background In paper based CQV programs, the inspection process focuses on reports and execution binders; the reports summarize the conclusions of a specific study, and the execution binder provides the documented evidence used to support the conclusions in the report. Can you describe the audit trail features of this application?
4,5,6 However, these benefits are contingent on the ability to generate comprehensive, high-quality analytical and PK data packages. 10 The package, once adopted, is expected to introduce changes to regulatory exclusivity, market access, and competition rules for medicines, including biosimilars, across the EU. Document 9286/25.
Revised for 2023, the Parenteral Drug Association (PDA) has published an update to its Technical Report No. Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types.
While it officially applies to the manufacture of sterile medicinal products in the European Union, the revised EU Good Manufacturing Practice (GMP) Annex 1 effectively reset the benchmark for quality standards across the globe on 25 August 2023. Register your details to read more The post How ready are you?
The document was adopted by EMA’s Management Board at its December meeting. Work has already begun with the ongoing public consultation on the AI reflection paper, open until the end of 2023. The plan was prepared by the Big Data Steering Group (BDSG), a joint initiative between HMA and EMA.
Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. The compliance dates were first published in 2013, and subsequently updated in various guidance documents and regulations published by FDA.
Marketing Packages Taking part in the Excellence Awards offer your company many benefits including being able to tell the market, new and prospective clients about your achievement. For full details on the benefits, the scale of our audience and the marketing packages on offer please download the RESEARCH GUIDE.
billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030.
Tue, 01/10/2023 - 12:15. 10 January 2023. The Robotic Session during the 2023 ISPE Aseptic Conference in Bethesda, MA on 6-7 March has been established for several years. This can be found seven times in the entire document. We both agree that the next aseptic conference in 2023 will be full of interesting topics.
Given that multiple work packages may often start or end together, or else take longer than others ( Figure 1 ), the introduction of new PAT requires assessment and planning by multiple departments. Any documentation, such as validation reports then helps with compliance and later regulatory submissions and requests.
These standardised documents provide meticulously curated and scientifically approved information. References European Commission, (26 April 2023). European Commission, (28 June 2023) “Access to essential services: key challenges for the most vulnerable – report” Euractiv (26 September 2023). Euractiv (6 October 2023).
The long-awaited final rule, which we last discussed in a July 2023 blog post and have tracked in our March 2023 and March 2022 posts, aims to harmonize quality management system requirements for medical devices with requirements set forth by other regulatory authorities around the world. Notably, Part 820 will look different.
Although the organisation previously shared a draft version of the report in February, the revised document features new details on the drugs’ potential fair pricing. Obeticholic acid will be in the spotlight when an approval package for its use in NASH will be discussed at a Gastrointestinal Drugs Advisory Committee meeting on May 19.
CMC Requirements for New Drug Registration in Latin America Trudy Patterson Tue, 05/09/2023 - 11:23 Features May / June 2023 CMC Requirements for New Drug Registration in Latin America Aicha Otmani Flavia C. Additional required information beyond ICH guidelines, or non-value-added documents (e.g.,
As such there’s a growing question of how the industry will improve the sustainability profile of its existing medicines and ensure that sustainability is designed into new medicines, such as products, with a reduced environmental risk, greener manufacturing technologies, and recyclable delivery systems and packaging.
™ Roadmap Trudy Patterson Thu, 05/11/2023 - 13:25 Technical May / June 2023 Methodology to Define a Pharma 4.0™ ™ Roadmap Emmie Heeren AREND JAN WASSINK Venkateshwar Rao Nalluri, PhD Sebastian NIEDERHAUSER 1 May 2023 In the context of data integrity, data flows are essential. Methodology to Define a Pharma 4.0™ to Industry 4.0
And as of December 2023, BCBS covers nearly 118 million people , which is about 1 in 3 Americans. per package, which is equivalent to about $16,188 per year. How to check whether your BCBS plan covers Wegovy The first step in determining if Wegovy is covered by your plan is to check your plan documents.
A Proposal for a Comprehensive Quality Overall Summary Trudy Patterson Wed, 03/29/2023 - 13:14 Features May / June 2023 A Proposal for a Comprehensive Quality Overall Summary Roger Nosal Connie Langer Beth Kendsersky Jennifer L. Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Brown Megan E.
Documentation has experienced the same incredible advancements and that has significant impacts on industries that are dependent on it, such as the life sciences industry, consumer packaged goods manufacturers, and businesses involved in other highly regulated fields.
A Proposal for a Comprehensive Quality Overall Summary Trudy Patterson Wed, 03/29/2023 - 13:14 Online Exclusives A Proposal for a Comprehensive Quality Overall Summary Roger Nosal Connie Langer Beth Kendsersky Jennifer L. Concept Paper: M4Q(R2) Common Technical Document on Quality Guideline.” Brown Megan E. McMahon Timothy J.N.
5 However, the benefits are well documented. Sustainable pharma packaging: breaking down the barriers to adoption Over two years it resulted in approximately 52,000 inhalers being returned, equating to approximately 305 tonnes of CO 2. 2023; 11 (17), 6510-6522. 2023; 33:5. 2023; 33(1): 24. Cited 2024August].
The UK Health Security Agency’s ‘Start smart then focus’ AMS toolkit – first published in 2011 and most recently updated in September 2023 – makes evidence-based recommendations on effective AMS practices in hospitals, including appropriate management of penicillin allergy labels.
Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” Tobolowsky & Richard A. It finalized a draft guidance published in 2022.
Life-Cycle Approach to Cleaning Topical Drug Products Trudy Patterson Wed, 01/11/2023 - 10:17 Technical January / February 2023 Life-Cycle Approach to Cleaning Topical Drug Products Dijana Hadziselimovic Kamini I. A draft of these updates should be provided with the validation documentation and implemented upon successful execution.
Pilot participants were provided a technical package containing all resources needed to accurately calculate the SP-TAT-PH measure. Barriers to Optimizing TAT Prior authorizations are often responsible for longer TAT, with many participants expressing the burden of rigorous documentation required by payers.
In 2023, the Royal College of Emergency Medicine and the UK Clinical Pharmacy Association recommended all EDs have a dedicated pharmacist and, as of 2024, approximately 77 of 170 UK EDs (45%) have a clinical pharmacy service. Recognition is about developing concerns or suspicions as to whether a patient has been maltreated.
Environmental Sustainability in Biopharmaceutical Facility Design Trudy Patterson Wed, 03/15/2023 - 09:13 Online Exclusives March / April 2023 Environmental Sustainability in Biopharmaceutical Facility Design William G. Table 1: Facility environmental sustainability tools and example values. 7 An integrative (vs. 7 An integrative (vs.
Trudy Patterson Mon, 09/11/2023 - 06:10 Features September / October 2023 Air Speed Qualification: At Working Position or Working Level? 3 Lastly, the WHO published the new guideline under their framework in January 2023 as Annex 2. x, a free and open-source computational fluid dynamics (CFD) software package.
The facility would need to be designed, constructed, commissioned, and validated for occupancy and use by the summer of 2023, when projected growth would test the capacity of existing facilities. Going Live Following design and permitting, project construction began October 2021 and is now nearing completion in spring 2023 (see Figure 6).
While the document itself is a quarter of a century old at this point, it is laid out in such a way that relevancy is maintained. This guideline forms the key document referenced by regulatory authority documents that detail structural characterization requirements of biopharmaceuticals. Analytical Validation (ICH, 2023).
Sustainability: Corporate Ambition, Governance, & Accelerated Delivery Trudy Patterson Tue, 03/07/2023 - 09:14 Features March / April 2023 Sustainability: Corporate Ambition, Governance, & Accelerated Delivery Guy Wingate, PhD Ylva Ek Patricia M. that apply to the scope of activities undertaken by their organization.
In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.
” Its investigation into foreign FDA inspections is shocking (April 19, 2023): “A ProPublica analysis of FDA inspection data as of April shows that the agency’s inspections of overseas drug manufacturers, located mostly in India and China, has dropped precipitously even as the number of manufacturers has remained relatively steady.
Considerations for a Decentralized Manufacturing Paradigm Trudy Patterson Mon, 09/11/2023 - 06:47 Features September / October 2023 Considerations for a Decentralized Manufacturing Paradigm Marquerita Algorri, PhD Ting Wang, PhD Jocelyn X. 7 June 2023. Accessed 14 April 2023. Updated January 2023. McQueen Nina S.
Gaulkin — In May 2023, we posted about a CMS proposed regulation that sought to make a wide variety of changes to the Medicaid Drug Rebate Program (MDRP), including a new “price verification survey,” and a controversial proposal to require “stacking” of discounts to different customers when determining best price.
An Evaluation of Postapproval CMC Change Timelines Trudy Patterson Sun, 09/10/2023 - 11:22 Features September / October 2023 An Evaluation of Postapproval CMC Change Timelines Rob Harris, PhD Meike Vanhooren Kara Follmann, PhD Beth Kendsersky Timothy J.N. Accessed 14 June 2023. Accessed 14 June 2023. Published 2021.
Pharma Investment Trend Report: What We’re Watching in 2023.” Published 13 January 2023. Updated 10 January 2023. addresses the risk-based decision-making process as a consequence of the previously defined level of formality, alongside the levels of effort and documentation. Adopted January 2023. Zydney, and J.
The 1,000-plus page document is full of tax and spending cuts, including some significant changes that will impact pharma and the larger healthcare industry. Plus, the package would require all rebates or discounts received by PBMs to be passed on to a Medicare Part D plan sponsor, according to a recent brief by Mintz.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content